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More individualised and physiological therapy is now possible
THE DISCOVERY OF INSULIN and its introduction as ther-
apy for type 1 diabetes in the early 1920s was understanda-
bly thought to have resolved the management of this fatal
disease. However, within a few decades the spectre of
diabetes complications arose, and it became apparent that
more sophisticated therapy was needed. Since then, a wide
range of insulin preparations and therapeutic strategies have
been developed in attempts to mimic natural insulin pro-
files, while bovine and porcine insulins have been largely
replaced by recombinant human insulin. Most recently,
recombinant DNA technology has allowed the insulin mole-
cule itself to be modified to create insulins with vastly
altered pharmacokinetic characteristics (the insulin ana-
logues). These, along with new modes of delivery and
monitoring, now hold promise of even more individualised
and physiological treatment.
In the second half of the 20th century, type 2 diabetes was
recognised as a disease, along with its related disorders,
including the metabolic syndrome. Type 2 diabetes is now
increasing rapidly in prevalence and also requires new
therapeutic strategies.
Type 1 diabetes
In the past decade, two major advances have improved the
care of patients with type 1 diabetes. First, we understand
the unequivocal relationship between metabolic control and
vascular complications;1-4 suboptimal blood glucose control
has a lasting harmful effect even if control improves later.
Second, the development of new forms of insulin with more
rapid onset or longer duration of action (insulin analogues)
and new forms of delivery (eg, continuous pumps and
aerosol sprays), as well as advances in glucose monitoring,
provide more options for those affected.
Intensive diabetes management
Because of the relationship between suboptimal glycaemic
control and vascular complications, intensive management
to minimise hyperglycaemia is now recommended for all
patients. This may include more frequent administration of
insulin (up to four times daily) or use of different insulin
types (eg, rapid- and long-acting insulin analogues), as well
as more frequent blood glucose measurements and changes
to insulin dose than in conventional therapy.
Intensive schedules need to be individualised to suit
patient age and lifestyle. For example, adults and adoles-
cents generally need intermediate-acting insulin before bed
for night-time control. Some school-aged children need
short-acting insulin at afternoon tea rather than lunch-time
to prevent late-afternoon hyperglycaemia, while many pre-
school-aged children can be managed with one dose of
intermediate-acting insulin in the morning and small doses
of rapid-acting insulin analogues (see below) to prevent
hyperglycaemia later in the day. The imminent availability of
long-acting insulin analogues will change these schedules
considerably. Insulin pumps may be useful for some patients
with frequent hypoglycaemia or hypoglycaemic unaware-
ness.
Intensive therapy is more demanding for patients and
their families, and adherence is obviously critical to its
success. Patient views are therefore central to management
decisions. For example, an adolescent who struggles to
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ABSTRACT
■ As suboptimal blood glucose control has a lasting harmful 
effect even if control improves later, intensive insulin 
therapy to minimise hyperglycaemia is now 
recommended for all patients with type 1 diabetes.
■ The new rapid- and long-acting insulin analogues offer 
more physiological insulin profiles than traditional insulin 
preparations.
■ Continuous insulin infusion (“pump therapy”) may provide 
a solution for some patients with frequent hypoglycaemia 
or hypoglycaemic unawareness.
■ Continuous blood glucose monitoring reveals 
postprandial hyperglycaemia and asymptomatic 
nocturnal hypoglycaemia and may be especially useful for 
programming overnight basal insulin rates for pump 
therapy.
■ In type 2 diabetes, management should change with 
disease progression; introduction of insulin should not be 
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delayed if metabolic control becomes suboptimal.
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comply with two injections a day is unlikely to manage four
injections (see case report, Box 1). However, for most
patients, the demands of achieving good control are less
than the consequences of poor control.5 In adolescents,
good control improves quality of life and reduces the burden
perceived by their parents.5
The limiting factor preventing ideal glycaemic control
remains hypoglycaemia. Glucagon secretion is blunted early
in the course of type 1 diabetes, increasing the patient’s
vulnerability to hypoglycaemia. Furthermore, the blood
glucose threshold for release of catecholamines, which both
stimulate glucose production and produce warning symp-
toms such as sweating and trembling in response to hypogly-
caemia, is lowered in patients with better glycaemic control,
even more so during sleep.6 Continuous glucose monitoring
devices reveal the frequency of nocturnal hypoglycaemia
and the limitations of conventional blood glucose monitor-
ing. Both the new insulin analogues and continuous subcu-
taneous insulin therapy hold promise of improving control
without the attendant risk of hypoglycaemia.
Insulin analogues
In the past, the pharmacokinetic characteristics of insulin
preparations have been modified by mixing with substances
that delay absorption (eg, protamine and zinc) and by
varying crystal size. Recombinant DNA technology has now
made possible the creation of analogues of human insulin
with altered pharmacokinetic characteristics (Box 2).
Rapid-acting analogues: These are also known as rapid-
onset and ultra-short-acting insulins and include insulin
aspart and insulin lispro. They were created by modifying
the amino acid sequence of the insulin B chain (substituting
aspartic acid for proline at position 28 [aspart] and reversing
proline and lysine at positions 28 and 29 [lispro]).
These analogues have the advantages that:
■ they follow better the rise in blood glucose level after
eating than conventional short-acting insulins, thereby
reducing postprandial hyperglycaemia and between-meals
hypoglycaemia;
■ their very rapid onset of action allows them to be
injected immediately before meals or even after eating,
1: Case report — an adolescent with type 1 diabetes
Presentation: A 13-year-old high school student 
with a 5-year history of type 1 diabetes presented 
for follow-up at a diabetes clinic. She had been 
treated since diagnosis with twice-daily injections 
of short-acting  plus intermediate-acting human 
insulin (1.3 U/kg per day, Protaphane/Actrapid or 
Humulin NPH/Humulin R). She monitored her 
blood glucose level approximately once daily and 
reported minimal symptomatic hypoglycaemia. 
She played badminton on most evenings.
Investigations: Her HbA1c level was 9.7%, 
indicating poor glycaemic control. Body mass 
index (BMI) was 19 kg/m2 (RR, 20–25 kg/m2).
Management: After discussion with the 
endocrinologist and diabetes educator, the girl 
agreed to try a more intensive basal–bolus 
regimen injected with a pen delivery device to 
improve her glycaemic control. This regimen 
comprised:
■ an intermediate-acting human insulin before bed 
(Protaphane or Humulin NPH); and
■ a rapid-acting insulin analogue three times daily 
before meals (NovoRapid or Humalog).
She was asked to increase blood glucose monitoring to at least three 
to four times daily (before and after eating), and was scheduled for 
follow-up after 3 months.
3-month follow-up: Her HbA1c level had risen to 10.8%, and BMI had 
fallen to 17 kg/m2. Menstrual cycles remained regular. She found it 
difficult to adhere to the insulin schedule and rarely took lunchtime 
insulin at school.
Further management: Her insulin schedule was changed to three 
times daily, comprising:
■ a mixture of short- and intermediate-acting human insulin in the 
morning (Protaphane/Actrapid or Humulin NPH/Humulin R);
■ a rapid-acting insulin analogue before the evening meal 
(NovoRapid or Humalog); and
■ an intermediate-acting human insulin before bed (Protaphane or 
Humulin NPH).
■ Doses were to be adjusted frequently depending 
on blood glucose profile, expected food intake 
and activity. The importance of monitoring blood 
glucose frequently was repeated. She also saw a 
diabetes educator and a dietitian at this visit to 
assess her current diet and to help individualise 
the regimen accordingly. Her family was to have 
weekly telephone contact from the diabetes 
educator for support in insulin adjustment, and 
she was to have follow-up clinic review in 6 weeks. 
■ Blood glucose control may deteriorate during 
adolescence because of physiological changes 
associated with puberty and difficulties with 
adherence.
■ Because of the relationship between poor 
glycaemic control and vascular complications, 
intensive management should be offered to all 
people with type 1 diabetes.
■ As an intensive schedule is often difficult to 
introduce in adolescence, most units caring for this 
age group begin this schedule from diagnosis. When introducing an 
intensive schedule, a diabetes educator and dietitian experienced 
with adolescents should be involved, with frequent contact to help 
adherence; in this case, 3-monthly review was inadequate.
■ Deteriorating glycaemic control, indicated by a rising HbA1c level 
with the initiation of intensive diabetes management, suggests 
poor adherence.
■ A three-times-daily insulin schedule avoids a lunch-time 
insulin dose at school and, as adherence was already a problem 
for this patient, might be the best compromise at this stage.
■ While the girl’s weight loss may have been related to the 
deterioration in metabolic control, the possibility of an eating 
disorder should be considered. If weight loss continued, 
referral to a psychologist or psychiatrist might be advisable. 
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which is especially useful in young children with erratic
eating patterns.
Their disadvantages are:
■ shorter duration of action than traditional short-acting
human insulins, which could cause preprandial hypergly-
caemia.
The short-acting analogues are available on the Pharma-
ceutical Benefits Scheme.
Long-acting analogues: These were created by substitut-
ing and adding amino acids to the insulin molecule
(glargine) and by adding a fatty acid chain, which enhances
binding to albumin (detemir).
The long-acting analogues have the advantages of:
■ more reproducible absorption than conventional long-
acting insulins;
■ a flat dose profile with a low peak of action, which
provides more predictable background control than the
intermediate-acting insulins, without the unwanted peaks of
action around lunchtime and during the night.
Initial studies indicate that the long-acting analogues
reduce the risk of nocturnal hypoglycaemia and produce a
modest reduction in fasting blood glucose levels compared
with intermediate-acting preparations.7 Neither is as yet
available on the Pharmaceutical Benefits Scheme (PBS).
There are few data on the relative benefits of administration
by pump versus multiple daily injections for glargine or
detemir as the basal insulin, but better night-time blood
glucose control with pump therapy has recently been
described.8
New delivery systems
Pump therapy: The effectiveness of continuous subcuta-
neous insulin infusion (pump therapy) has been rediscov-
ered (Box 3). First used in the 1970s and 1980s, pump
therapy has been reintroduced with improved technology.
Small amounts of a rapid-acting insulin analogue are
infused, usually into the abdomen or buttocks, at a basal
rate, which can be varied, with extra boluses calculated for
each meal and snack. The major advantages are less variable
absorption and improved insulin pharmacokinetics. Varying
the basal rate can help regulate overnight blood glucose
levels. Pump therapy is suitable for motivated patients,
particularly those with frequent hypoglycaemic episodes or
hypoglycaemic unawareness, as most studies show reduced
hypoglycaemia.9,10 Because the infused insulin is rapid-
acting, mechanical interruption of the pump can rapidly
lead to ketosis, which is of particular concern in pregnancy.
Pump therapy must therefore be accompanied by frequent
blood glucose monitoring. Private health insurance compa-
nies now subsidise the cost of the pump and some consum-
ables, but there is no government funding. As for all
therapies, it is essential that the patient is central to the
choice of pump therapy. This is also important when the
patient is a child or adolescent, whose views may differ from
those of their parents.
Aerosols: Aerosolised insulins for delivery by inhalation are
under active investigation, with Phase III studies completed.
These insulins provide effective cover for meals in combina-
tion with once-daily, long-acting, subcutaneous insulin.
However, aerosol delivery requires six times as much insulin
for the same effective dose as subcutaneous injection, which
may create a cost barrier to widespread use. Also, the long-
term safety of delivering large amounts of insulin to the
alveolae is not known.
At present, all systems deliver insulin to the systemic
circulation rather than the enteroportal circulation. Sys-













Humalog Lispro 15 min 1–2 3.5–4.5
NovoRapid Aspart 10–20 min 1–3 3–5
Biphasic analogue mixtures
Humalog Mix25 Lispro + lispro 
protamine 
suspension
15 min 2 24
NovoMix 30 Aspart + aspart 
protamine 
crystallised 
10–20 min 1–4 24
Long-acting analogues‡
Lantus Glargine 1–2 h 6 +§ 24 +
Not yet named Detemir 1–2 h 6–8 20
Conventional human insulins
Short-acting insulins
Actrapid Neutral 30 min 2.5–5 8
Humulin R 30 min 2–4 6–8
Intermediate-acting insulins
Humulin NPH Protamine 
suspension
1h 4–10 16–18
Protaphane 1.5 h 4–12 24
Humulin L Zinc 
suspension 
(lente)
2 h 6–12 24






2 h 6–20 24 +
Ultratard 4 h 8–24 28
Biphasic mixtures





30 min 2–12 16–18
Mixtard 30/70 30 min 2–12 24
Humulin 20/80 30 min 1–9.5 17–19
Mixtard 20/80 30 min 2–8 24
Humulin 50/50 30 min 2–12 16–18
Mixtard 50/50 30 min 4–8 24
* Most preparations are available in a variety of presentations, including vials, 
cartridges for insulin pens, and pre-filled pens or devices. Humalog and 
Humulin preparations are manufactured by Eli Lilly, Lantus by Aventis, 
and all other listed preparations, including detemir, by Novo Nordisk.
† None of the insulin analogues are registered for use in pregnancy. 
‡ The long-acting analogues are not currently registered in Australia. 
§ No defined peak of action.
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temic delivery contributes to the insulin resistance associ-
ated with obesity and adolescence and is a major barrier to
physiological insulin replacement. However, a method of
accessing the enteroportal circulation is not currently in
sight.
New monitoring systems
Continuous blood glucose monitoring: Intermittent
measurements of capillary blood glucose give a limited
glimpse of blood glucose levels, which may fluctuate widely
over 24 hours. The recent introduction of systems for
continuous blood glucose monitoring is an exciting
advance11,12 (Box 4). Continuous monitoring reveals post-
prandial fluctuations in glucose level and asymptomatic
nocturnal hypoglycaemia, and is likely to be especially useful
in programming overnight basal insulin rates for pump
therapy. Continuous monitoring systems available in Aus-
tralia measure interstitial blood glucose via an indwelling
cannula in the abdomen or buttocks. However, they are
expensive ($5000 or more) and, at present, are most
applicable for use by diabetes centres which lend devices to
patients for restabilisation. Devices under investigation have
alarms to alert patients to glucose levels outside a target
range and provide immediate read-outs.
Non-invasive blood glucose monitoring: Frequent
automatic glucose readings can be obtained non-invasively
through the process of reverse iontophoresis, in which a low
electric current pulls glucose molecules through the skin for
collection in a gel disc. A device that is worn like a
wristwatch is approved for patients aged over 7 years in the
United States, but its cost (about US$1000 for the device
and more than US$100 per disposable 12-hour sensor)
limits more widespread use. It is not yet available in routine
practice in Australia.
HbA1c measurement: Measurement of glycosylated hae-
moglobin (HbA1c) remains the criterion standard to judge
the outcome of diabetes management. Rapid measurement
with a desktop device expedites assessment and education.
Results of longitudinal studies now allow accurate predic-
tion of the risk of vascular complications for a given HbA1c
level3,4 (Box 5). This can be very useful when counselling
patients. For example, a teenager can be advised that large
trials show that reducing the HbA1c level from 9% to 8%
and maintaining the reduction during adolescence reduces
the risk of proliferative and severe non-proliferative retino-
pathy in young adulthood by 70%–80%.3
Other advances
Education and psychological support: With the advent
of intensive therapy and its greater demands on patients and
their families, counselling and education are becoming even
more important in achieving compliance, particularly in
adolescents. However, as long-term risk of vascular compli-
cations can be predicted more accurately from HbA1c level,
it is easier for doctors to counsel and encourage intensive
management.1-4 Furthermore, as doctors have become more
certain about the need for intensive management, it is our
impression that patients and their families have accepted
and coped better with it. Indeed, mean HbA1c levels in
Australian children have improved from 10% in the 1980s to
around 8% in 2003.14
Coping-skills training has been shown to improve meta-
bolic control and quality of life in adolescents.15 This
intervention, like all successful interventions in type 1
diabetes, needs to be intensive, and support must be
sustained.
The indispensable role of the diabetes educator and
dietitian in the multidisciplinary team has long been recog-
nised. Dietary management and education is now more
comprehensive and includes the concept of the glycaemic
indices of food.16 Educators’ roles are becoming more
specialised, both for different age groups and, as technology
progresses, for different monitoring and delivery systems.
4: Continuous blood glucose monitoring
Blood glucose profile obtained by continuous subcutaneous 
monitoring in an adolescent with type 1 diabetes, showing 
night-time hypoglycaemia (blood glucose level <3.0mmol/L) 
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3: “Pump therapy” (continuous subcutaneous 
insulin infusion)
Insulin is infused into the abdomen or buttocks by a programmable 
pump which can be worn on the belt similarly to a pager.
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New use of old drugs: Adding metformin to the treatment
regimen for type 1 diabetes can improve metabolic control
by reducing insulin resistance, a problem in both obese
patients and adolescents with diabetes, in whom the physio-
logical insulin resistance of puberty is exaggerated, necessi-
tating high insulin doses.17 However, metformin is suitable
only for patients with low alcohol intake and normal renal
and hepatic function who remain compliant with insulin
therapy.
Glucagon in small frequent doses (< 0.15 mg up to 6-
hourly) can prevent hypoglycaemia (and resulting hospital
admissions) in patients with reduced oral intake, including
children with viral gut infections.18
Type 2 diabetes
Type 2 diabetes mellitus generally forms part of the “meta-
bolic syndrome”, which is characterised by insulin resist-
ance, obesity and a range of cardiovascular risk factors, as
discussed previously in this series.19 Advances in manage-
ment of type 2 diabetes include recognition of the need for
early and aggressive management of insulin resistance and
associated abnormalities, such as dyslipidaemia, hyperten-
sion and albuminuria.
Therapy for type 2 diabetes
Therapy for type 2 diabetes should be tailored to the
pathological process that is most prominent at different
stages of the disease (see case report, Box 6).
Increase insulin sensitivity: Early in the disease process,
the aim should be to target insulin resistance with diet and
exercise plus metformin therapy. A weight loss of 5 kg leads
to a 25%–50% reduction in insulin resistance (J Prins,
unpublished data). Metformin is tolerated by most patients
if started at a low dose (eg, 250–500 mg/day), which is
slowly increased depending on blood sugar response and
tolerance.
The thiazolidinediones (rosiglitazone and pioglitazone)
are newer insulin-sensitising agents which are effective, but
have the disadvantage of causing some weight gain and fluid
retention. However, unlike metformin, they are safe in
patients with renal impairment. They are widely used
overseas but are not currently available on the PBS.20
Increase circulating insulin: If strategies to increase
insulin sensitivity are ineffective, the next step is to increase
circulating insulin level. Oral agents currently available in
Australia for this purpose are the sulfonylureas and the
newer glitinides. Metformin should be continued if the
patient is obese.
As sulfonylureas are potent and long-acting, hypoglycae-
mia is a significant clinical problem, but can be avoided with
careful dose titration. Sulfonylureas cause weight gain of a
few kilograms in most patients and lose efficacy with time,
either because of increasing insulin resistance (usually due
to the weight gain) or “secondary” pancreatic -cell failure.
Other than half-life differences, there is little to distinguish
later-generation sulfonylureas.
Glitinides (eg, repaglinide) are short-acting drugs that
increase insulin secretion. They are well tolerated but less
potent in clinical practice than the sulfonylureas. Their
advantage lies in their short half-life, making hypoglycaemia
less common, but pre-meal dosing is a disadvantage for
many patients. Glitinides are not currently available on the
PBS.
Exogenous insulin: If diabetic control remains, or
becomes, suboptimal when taking oral combination therapy
with metformin and a sulfonylurea, then insulin is indi-
cated.21,22 As evidence supporting the benefits of good
diabetic control is now overwhelming,13 any delay in intro-
ducing insulin in these patients is now considered unaccept-
able. It is important to educate patients that insulin is
usually necessary because of natural progression of the
disease and not necessarily because of any “failure” on their
part. It is therefore advisable to introduce the concept well
before necessary. A good “selling point” is that insulin often
substantially improves how patients feel.
With currently available insulin preparations and adminis-
tration devices, it is straightforward to develop an acceptable
“physiological” insulin-replacement regimen for almost all
patients.21,22 Newer analogue insulins (including mixtures)
have a definite place in the management of type 2 diabetes
and contribute to the excellent choices available.
There is little point in continuing sulfonylurea or glitinide
therapy after introducing insulin. Advantages of ceasing oral
agents are simplification of therapy, less chance of drug
interaction, reduced costs and improved compliance. How-
ever, metformin should be continued in obese patients, as it
helps maintain weight and allows lower insulin doses to be
used. Pioglitazone is the only insulin-sensitiser available for
combination with insulin in Australia for patients with renal
impairment.
Monitoring of type 2 diabetes
With recognition of the importance of blood sugar control
in type 2 diabetes, aggressive monitoring is now essential.
Monitoring of HbA1c level is central to management of type
2 diabetes and may be simplified by the new desktop
5: Glycosylated haemoglobin (HbA1c) levels and 
diabetes complications
■ In normal glucose tolerance, HbA1c level is usually < 5%.
■ In diabetes, an HbA1c level > 8% indicates poor glycaemic control 
and a need to assess therapy and adherence.
■ A decrease in HbA1c level of 1 percentage point has been shown 
to lead to:
➤ a 10% reduction in microvascular complications in type 2 
diabetes (UKPDS trial13) and
➤ a 20%–30% reduction in microvascular complications in type 1 
diabetes (DCCT trial3), with associated less significant 
reductions in macrovascular complications.
■ In treating diabetes, the benefits of decreasing HbA1c level must 
be weighed against the risk of side effects and the ability of the 
patient to comply; thus, the “target” HbA1c level must be 
individualised.
■ HbA1c levels < 6% are very difficult to achieve in diabetes without 
serious side effects, such as life-threatening hypoglycaemia.
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measuring device. It is noteworthy that 1–2 days of hyper-
glycaemia (eg, during an infection) will increase HbA1c level
for some weeks. HbA1c level is falsely low in some haemo-
globinopathies and in states of increased red cell turnover,
such as haemolysis. In these cases, the level of fructosamine
(glycosylated albumin) can be measured. This reflects gly-
caemic control over weeks, rather than the 2–3 months
reflected by HbA1c level. Its assay is less reliable, and it is
not indicated routinely.
Home blood glucose monitoring is crucial for diabetic
control. In type 2 diabetes, insulin resistance makes good
control of postprandial blood sugar very difficult. We there-
fore recommend that fasting blood glucose level be recorded
at least twice daily at different times (before meals and
before bed) during the week so that patterns of glucose
control can be identified.
Drugs on the horizon
Insulin analogues: Many of the new insulin analogues will
have a place in management of type 2 as well as type 1
diabetes.
Dual PPAR/ agonists: The nuclear hormone receptor
PPAR (peroxisome proliferators-activated receptor) is
involved in glucose and, to a lesser extent, lipid metabolism
and is a target of the thiazolidinediones (glitizones). Drugs
are currently under trial which act both on this receptor and
a related receptor involved in lipid metabolism, which is
targeted by the fibrates. These dual PPAR agonists will
probably have an important role in managing type 2 diabe-
tes and the metabolic syndrome within a few years.
Orlistat: This lipase inhibitor is currently indicated for use
in obesity. Clinical trials have demonstrated its usefulness as
an insulin-sensitising agent, with the added benefit of weight
management.23 Overall efficacy appears similar to that of
metformin or sulfonylurea.
Insulin secretagogues: These include the gut-derived
hormones (incretins), such as glucagon-like peptide-1
(GLP1) and gastric inhibitory peptide. GLP-1 analogues
and receptor agonists are currently under clinical trial and
show definite promise for patients with type 2 diabetes.
Administration is parenteral, but initial trial results demon-
strate efficacy in blood sugar control, minimal risk of
hypoglycaemia, and the associated benefit of weight loss. A
related approach is oral administration of dipeptidase IV
inhibitors, which effectively increase GLP-1 levels.24
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